Provided by Tiger Trade Technology Pte. Ltd.

Exicure, Inc.

2.81
+0.05001.81%
Pre-market: 3.000.1900+6.76%05:48 EDT
Volume:15.45K
Turnover:41.72K
Market Cap:17.91M
PE:-3.58
High:2.81
Open:2.76
Low:2.63
Close:2.76
52wk High:10.80
52wk Low:2.63
Shares:6.37M
Float Shares:2.33M
Volume Ratio:0.79
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7854
EPS(LYR):-0.7854
ROE:-92.47%
ROA:-43.46%
PB:4.56
PE(LYR):-3.58

Loading ...

Exicure delays filing quarterly report, seeks five-day extension under SEC rules

Reuters
·
May 16

BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)

Reuters
·
Apr 23

Exicure partners with Adbiotech to co-develop Burixafor combination therapies

Reuters
·
Apr 23

Exicure Announces Co-Development Agreement With Adbiotech for Burixafor (Gpc-100)

THOMSON REUTERS
·
Apr 23

Exicure names Young Seung Ko chief operating officer

Reuters
·
Apr 11

Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation

THOMSON REUTERS
·
Apr 03

Exicure reaches settlement in stockholder derivative litigation, adopts governance reforms

Reuters
·
Apr 03

Exicure board changes; Sangjin Yeo resigns from board and audit committee effective March 27, 2026

Reuters
·
Mar 28

Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.

Benzinga
·
Mar 26

Press Release: Exicure, Inc. Reports Full Year 2025 Financial Results

Dow Jones
·
Mar 26

Top News Today: Stocks Slide, Treasury Yields Rise Amid Oil Shock

Dow Jones
·
Mar 21

Top News Today/Canada: Retail Sales Rose 1.1% in January

Dow Jones
·
Mar 21

Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing

THOMSON REUTERS
·
Feb 18

Exicure Inc - Andy Yoo Resigns as CEO and President of Exicure - SEC Filing

THOMSON REUTERS
·
Feb 18

Exicure Inc. Appoints Jung Soo Kim as CEO and Gyuyeob Lee as Interim CFO

Reuters
·
Feb 18

Exicure Inc. Appoints Three New Directors as CEO and CFO Resign

Reuters
·
Feb 11

Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an

Reuters
·
Feb 05

Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients

Reuters
·
Feb 05

Exicure Achieves Milestone in Collaboration with GPCR Therapeutics

Reuters
·
Jan 23

Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings

TIPRANKS
·
Jan 21